{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Number of patients who experienced at least a grade 2 toxicity with \"definite,\" \"probable,\" or \"possible\" attribute to study treatment, according to the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}